Johnson & Johnson Innovation and the Biomedical Advanced Research and Development Authority (BARDA) have announced the ‘Blue Knight Resident QuickFire Challenge: Accel
Eleven new digital health start-ups have graduated from PharmStars’ latest education and mentoring programme – brought together on the common theme of finding new ways to use real-world evi
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh